SLCTR/2010/004招募中未知
Metformin for treatment of atypical antipsychotic induced weight gain: a randomized double blind placebo controlled trial
Faculty of Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients diagnosed with schizophrenia or schizoaffective disorder according to ICD-10 research criteria
- •2.Age > 18 years
- •3.Treated with olanzapine, risperidone or clozapine
- •4. Gained more than 10% of the pre treatment body weight
排除标准
- •1. Those concurrently treated with other psychotropics known to cause weight gain, (lithium carbonate, carbamazepine, sodium valproate and antidepressants)
- •2. Patients too ill to consent
- •3. Patients previously diagnosed with diabetes
- •4. Pregnant patients
- •5. Patients with impaired renal functions before enrollment (Sample size calculation is based on an expected difference in weight of Body Weight Gain of between the 2 groups, a power of 80%, and a Type I error of 5%. Sample size required in each group=64)
研究者
相似试验
已完成
4 期
Metformin for Treatment Antipsychotic-induced Metabolic Syndrome in Bipolar Disorder PatientsBipolar DisorderNCT02644577China Medical University, China110
尚未招募
不适用
Treatment with metformin to reduce insulin requirements in Diabetes in PregnancyGestational diabetes mellitusSLCTR/2011/009one
已完成
2 期
Strategies to Reduce Antipsychotic-Associated Weight Gain in YouthWeight GainNCT00617240University of North Carolina, Chapel Hill9
已完成
4 期
Metformin for Treatment of Antipsychotic-induced DyslipidemiaDyslipidemiaNCT01778244Central South University162
已完成
4 期
Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic AbnormalitiesMetabolic SyndromeNCT02751307Taipei Medical University WanFang Hospital55